Cedars-Sinai Medical Center - UCLA School of Medicine
Samuel Oschin Comprehensive Cancer Institute
Los Angeles, CA
Not currently accepting
Iberdomide vs. Observation Post Ide-Cel CAR-T
Randomized Phase 2 Study of Iberdomide Maintenance Therapy Following Idecabtagene Vicleucel CAR-T in Multiple Myeloma Patients
- CELMoD
- Maintenance
- Randomization
- Phase 2
Accepting patients
MagnetisMM-4
MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma
- Bispecific Antibody
- Gamma-Secretase Inhibitor
- BCMA
- Phase 1/2
Accepting patients
Low-Dose Radiotherapy for Bone Metastases
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
- Radiation
- Phase 2
Accepting patients
Autologous Stem Cell Transplant Post CAR-T
Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies
- Autologous Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 1
Not yet accepting
QXL138AM
A First-in-human Phase 1a/1b Study to Evaluate Safety and Tolerability of QXL138AM in Patients With Locally Advanced Un-resectable and/or Metastatic Solid Tumors and Multiple Myeloma
- Masked Immunocytokine (MIC)
- CD138
- Phase 1